GlobalData has analysed clinical trials initiated in Japan over the last five years according to their phases. This study captured records of 8,615 clinical trials across all diseases and phases that had a start date 1 January, 2012, and 31 December, 2016.
The total number of new clinical trials was 1,950 in 2012, decreasing to 1,516 in 2016. The most prominent decrease, at 16%, occurred in 2014.
Phase II Most Prominent
A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 55% and 62% across the period. The share of Phase I trials started at 11% in 2012 and decreased to 10% by 2016, as shown in Figure 1. Phase III trials’ contribution remained flat at 16% across the five-year period, whereas Phase IV trials increased in share from 11% to 16% in the first and last year, respectively.